



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Artificial Intelligence in Drug Discovery

Adarsh Mane*, Pankaj Chavan, Hanumant Gutte, Prashant Ghayal, Vinayak Prasad, Tanvi Mhatre

Research Scholar, Siddhi's Institute of Pharmacy, Nandgaon, Maharashtra, India.

ARTICLE INFO

Published: 26 May 2026

Keywords:

Artificial Intelligence, Drug Discovery, Deep Learning, Virtual Screening, Machine Learning

DOI:

10.5281/zenodo.20406167

ABSTRACT

Artificial intelligence (AI) has emerged as a transformative technology in the field of drug discovery, offering innovative solutions to overcome the limitations of traditional methods. Conventional drug discovery is often time-consuming, expensive, and associated with high failure rates. AI, particularly through techniques such as Machine Learning and Deep Learning, enables the rapid analysis of large and complex biological datasets, thereby accelerating the identification of potential drug candidates. AI plays a crucial role in various stages of drug discovery, including target identification, lead optimization, virtual screening, and drug repurposing. It enhances prediction accuracy for drug efficacy, toxicity, and pharmacokinetic properties, significantly reducing the time and cost involved in drug development. Additionally, AI-driven approaches support personalized medicine by tailoring treatments based on patient-specific data. Despite its advantages, challenges such as data quality, algorithm transparency, and regulatory concerns remain. This review highlights the key applications, benefits, and limitations of AI in drug discovery and discusses its future potential in revolutionizing pharmaceutical research and development. Overall, AI is poised to play a pivotal role in making drug discovery more efficient, cost-effective, and precise.

INTRODUCTION

Drug Discovery is a complex and systematic process that involves the identification of new chemical entities with potential therapeutic effects. It includes several stages such as target identification, lead compound discovery, preclinical testing, and clinical trials. The primary

goal of drug discovery is to develop safe, effective, and high-quality medicines for the treatment of various diseases^[1,2].

Traditionally, drug discovery has relied on experimental screening methods, trial-and-error approaches, and extensive laboratory research. While these methods have contributed significantly to the development of many

***Corresponding Author:** Adarsh Mane

Address: Research Scholar, Siddhi's Institute of Pharmacy, Nandgaon, Maharashtra, India...

Email ✉: maneadarsh12@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



successful drugs, they are associated with several limitations. One of the major challenges is the high cost, as developing a single drug can require billions of dollars. Additionally, the process is extremely time-consuming, often taking 10-15 years from initial discovery to market approval. Another critical issue is the high failure rate, where a large number of drug candidates fail during clinical trials due to lack of efficacy or safety concerns. In recent years, Artificial Intelligence has gained significant attention in pharmaceutical research due to its ability to analyze large datasets, identify patterns, and make accurate predictions. AI technologies, including Machine Learning and Deep Learning, have the potential to accelerate drug discovery by improving efficiency, reducing costs, and enhancing success rates. These advanced computational approaches enable faster target identification, optimized drug design, and efficient screening of compounds^[3,4].

The aim of this review is to highlight the role of artificial intelligence in modern drug discovery, its applications, advantages, challenges, and future perspectives in pharmaceutical research.

2. Basics of Artificial Intelligence^[5]

Artificial intelligence (AI) refers to the ability of computer systems to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making. In drug discovery, AI plays a crucial role in analyzing complex biological data and predicting drug behavior.

1. Machine Learning^[6,7]

Machine learning (ML) is a subset of AI that enables computers to learn from data without being explicitly programmed.

- Learning from data: Machine learning algorithms are trained using large datasets, such as chemical structures, biological activities, and clinical data. These algorithms identify patterns and relationships

within the data, allowing the system to improve its performance over time.

- Predicting drug activity: ML models can predict the biological activity of drug molecules by analyzing their chemical properties. This helps researchers identify promising drug candidates and reduces the need for extensive laboratory testing.

2. Deep Learning^[8]

Deep learning (DL) is an advanced form of machine learning that uses multiple layers of algorithms to process data.

- Neural networks: Deep learning is based on layered structures called neural networks, which consist of interconnected nodes (neurons). These layers process information step by step, enabling the system to learn complex patterns in large datasets.
- Pattern recognition in biological data: DL models are highly effective in recognizing complex patterns in biological and chemical data, such as protein structures, gene expression, and molecular interactions. This capability is essential for identifying drug targets and optimizing drug design.

3. Artificial Neural Network^[9,10]

Artificial Neural Networks (ANNs) are computational models inspired by the human brain.

- Brain-inspired computing model: ANNs mimic the structure and function of biological neurons. They consist of input, hidden, and output layers that process information and make decisions based on learned patterns.
- Used for predicting molecular properties: ANNs are widely used in drug discovery to predict important molecular properties such as solubility, toxicity, and binding affinity. This



helps in selecting suitable drug candidates with higher chances of success.

3. Applications of Artificial Intelligence in Drug Discovery^[11,12]

Artificial intelligence has significantly improved various stages of the drug discovery process by enhancing speed, accuracy, and efficiency.

1. Target Identification

Target identification is the first and most critical step in drug discovery, where specific biological targets such as proteins or genes associated with a disease are identified.

- AI helps identify disease-related proteins: AI algorithms analyze large biological datasets, including genomic and proteomic data, to identify proteins or genes involved in disease progression. By recognizing hidden patterns and relationships, AI can accurately predict potential drug targets, reducing the time required for early-stage research.

2. Drug Design

Drug design involves creating new chemical compounds that can interact effectively with the identified target.

- AI can design new drug molecules: AI models can generate novel molecular structures with desired pharmacological properties. These systems use existing chemical and biological data to design molecules that have higher efficacy, better safety profiles, and improved binding affinity to target proteins. This approach significantly accelerates the drug development process.

3. Virtual Screening

Virtual screening is a computational technique used to evaluate a large number of compounds for potential biological activity.

- AI screens thousands of compounds quickly:

AI-based virtual screening tools can rapidly analyze and filter millions of chemical compounds to identify those most likely to interact with a specific target. This reduces the need for time-consuming laboratory experiments and helps prioritize the most promising drug candidates.

4. Drug Repurposing

Drug repurposing involves finding new therapeutic uses for existing drugs.

- Existing drugs can be used for new diseases: AI can analyze clinical data, drug databases, and molecular interactions to identify new applications for already approved drugs. This approach saves time and cost, as the safety profiles of these drugs are already well established.
- Example - COVID-19: During the COVID-19 pandemic, AI was widely used to identify existing drugs that could be effective against the virus. This accelerated the discovery of potential treatments and supported rapid response efforts worldwide.

4. Advantages and Challenges of Artificial Intelligence in Drug Discovery^[13,14]

Artificial intelligence has brought significant advancements to drug discovery; however, it also presents certain challenges that must be addressed.

Advantages

1. Faster Drug Discovery

AI significantly accelerates the drug discovery process by automating data analysis and reducing the need for time-consuming experimental procedures. Tasks such as target identification, compound screening, and lead optimization can be



completed in a much shorter time compared to traditional methods.

2. Reduced Research Cost

The use of AI minimizes the need for extensive laboratory experiments and clinical trials in the early stages. By predicting the success or failure of drug candidates in advance, AI helps reduce unnecessary expenditure, making the overall process more cost-effective.

3. Better Prediction of Drug Properties

AI models can accurately predict important drug properties such as solubility, toxicity, bioavailability, and binding affinity. This improves the selection of suitable drug candidates and reduces the risk of failure in later stages of development.

4. Improved Success Rate in Clinical Trials

By analyzing patient data and predicting drug responses, AI increases the likelihood of success in clinical trials. It helps in selecting the right patient population and optimizing drug dosage, leading to better outcomes and reduced failure rates.

Challenges

1. Requirement of Large Datasets^[15]

AI systems require large amounts of high-quality data for training and accurate predictions. Incomplete or insufficient data can lead to unreliable results, limiting the effectiveness of AI models.

2. High Computational Cost

Advanced AI models, especially those based on deep learning, require powerful computing systems and specialized hardware. This increases the cost of implementation and may not be easily accessible to all research organizations.

3. Regulatory Issues

The integration of AI in drug discovery raises regulatory concerns related to safety, validation, and approval. Regulatory authorities require clear evidence of reliability and transparency in AI-based methods, which can be challenging to achieve.

4. Data Quality Problems^[16]

The accuracy of AI predictions depends heavily on the quality of input data. Errors, inconsistencies, or bias in the data can lead to incorrect predictions and affect the overall drug development process.

5. FUTURE PERSPECTIVES

The future of Artificial Intelligence in Drug Discovery is highly promising, especially when integrated with advanced technologies such as Bioinformatics and Big Data.

- **AI and Bioinformatics^[17]:** Bioinformatics involves the collection and analysis of biological data such as DNA sequences, protein structures, and gene expression profiles. When combined with AI, it enables faster and more accurate identification of drug targets, understanding of disease mechanisms, and prediction of drug-target interactions. This integration enhances the efficiency of early-stage drug discovery.
- **AI and Big Data^[18]:** The pharmaceutical field generates vast amounts of data from clinical trials, electronic health records, and research studies. AI can process and analyze this large-scale data to identify patterns, predict outcomes, and optimize drug development strategies. This leads to more informed decision-making and improved research productivity.
- **Impact on Personalized Medicine^[19]:** AI-driven analysis of patient-specific data allows the development of personalized treatment strategies. Drugs can be tailored according to an individual's genetic makeup,



lifestyle, and disease condition, leading to more effective and safer therapies.

Overall, the integration of AI with these technologies is expected to significantly accelerate drug discovery, reduce costs, and improve treatment outcomes in the future.

CONCLUSION

In conclusion, Artificial Intelligence in Drug Discovery has emerged as a powerful tool that is transforming the traditional pharmaceutical research process. By integrating advanced techniques such as Machine Learning and Deep Learning, AI enables faster identification of drug targets, efficient screening of compounds, and accurate prediction of drug properties. These capabilities significantly reduce the time, cost, and failure rates associated with conventional drug discovery methods. Despite challenges such as the need for high-quality data, computational resources, and regulatory validation, the benefits of AI far outweigh its limitations. Furthermore, the combination of AI with emerging fields like Bioinformatics and big data analytics is expected to enhance personalized medicine and improve patient outcomes. Overall, artificial intelligence holds great promise in revolutionizing drug discovery and will play a crucial role in shaping the future of pharmaceutical development.

REFERENCES

- Deng, J., Yang, Z., Ojima, I., Samaras, D., & Wang, F. (2022). Artificial intelligence in drug discovery: applications and techniques. *Briefings in Bioinformatics*, 23(1), bbab430.
- Mak, K. K., Wong, Y. H., & Pichika, M. R. (2024). Artificial intelligence in drug discovery and development. *Drug discovery and evaluation: safety and pharmacokinetic assays*, 1461-1498.
- Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M. T. (2016). Computational approaches in target identification and drug discovery. *Computational and structural biotechnology journal*, 14, 177-184.
- Dave, R., Giordano, P., Roy, S., & Imran, H. (2025). Identifying novel drug targets with computational precision. *Advances in Pharmacology*, 103, 231-263.
- Warwick, K. (2013). *Artificial intelligence: the basics*. Routledge.
- Sarker, I. H. (2021). Machine learning: Algorithms, real-world applications and research directions. *SN computer science*, 2(3), 1-21.
- Kühl, N., Schemmer, M., Goutier, M., & Satzger, G. (2022). Artificial intelligence and machine learning. *Electronic Markets*, 32(4), 2235-2244.
- Sarker, I. H. (2021). Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. *SN computer science*, 2(6), 1-20.
- Wang, S. C. (2003). Artificial neural network. In *Interdisciplinary computing in java programming* (pp. 81-100). Boston, MA: Springer US.
- Wu, Y. C., & Feng, J. W. (2018). Development and application of artificial neural network. *Wireless Personal Communications*, 102(2), 1645-1656.
- Dey, M., & Amour, A. (2025). Applications of artificial intelligence in drug discovery. *Emerging Topics in Life Sciences*, 8(2), 107-109.
- Chopra, H., Baig, A. A., Gautam, R. K., & Kamal, M. A. (2022). Application of artificial intelligence in drug discovery. *Current pharmaceutical design*, 28(33), 2690-2703.
- Tiwari, P. C., Pal, R., Chaudhary, M. J., & Nath, R. (2023). Artificial intelligence revolutionizing drug development: Exploring



- opportunities and challenges. *Drug Development Research*, 84(8), 1652-1663.
14. Mak, K. K., Wong, Y. H., & Pichika, M. R. (2024). Artificial intelligence in drug discovery and development. *Drug discovery and evaluation: safety and pharmacokinetic assays*, 1461-1498.
 15. Ferrari, A., Spagnolo, G. O., & Gnesi, S. (2017, September). Pure: A dataset of public requirements documents. In *2017 IEEE 25th international requirements engineering conference (RE)* (pp. 502-505). IEEE.
 16. Strong, D. M., Lee, Y. W., & Wang, R. Y. (1997). Data quality in context. *Communications of the ACM*, 40(5), 103-110.
 17. Ezziane, Z. (2006). Applications of artificial intelligence in bioinformatics: A review. *Expert Systems with Applications*, 30(1), 2-10.
 18. O'Leary, D. E. (2013). Artificial intelligence and big data. *IEEE intelligent systems*, 28(2), 96-99.
 19. Udegbe, F. C., Ebulue, O. R., Ebulue, C. C., & Ekesiobi, C. S. (2024). AI's impact on personalized medicine: Tailoring treatments for improved health outcomes. *Engineering Science & Technology Journal*, 5(4), 1386-1394.

HOW TO CITE: Adarsh Mane, Pankaj Chavan, Hanumant Gutte, Prashant Ghayal, Vinayak Prasad, Tanvi Mhatre Artificial Intelligence in Drug Discovery, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 7187-7192, <https://doi.org/10.5281/zenodo.20406167>

